Cartesian Therapeutics Holds Annual Stockholders Meeting

Cartesian Therapeutics ( (RNAC) ) has shared an announcement.

On June 13, 2025, Cartesian Therapeutics, Inc. held its Annual Meeting of Stockholders, where 21,868,804 shares were represented, accounting for approximately 84.31% of the company’s outstanding stock. During the meeting, three Class III Directors were elected to serve until the 2028 Annual Meeting, the compensation of the company’s named executive officers was approved on a non-binding basis, and Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.

The most recent analyst rating on (RNAC) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.

Spark’s Take on RNAC Stock

According to Spark, TipRanks’ AI Analyst, RNAC is a Neutral.

The company is facing significant financial challenges, with severe issues reflected in its financial statements. Despite technical indicators pointing to a bearish trend, the promising results from the Phase 2b trial offer a glimmer of hope. However, the negative P/E ratio underscores the financial difficulties, making this stock risky.

To see Spark’s full report on RNAC stock, click here.

More about Cartesian Therapeutics

Average Trading Volume: 94,574

Technical Sentiment Signal: Sell

Current Market Cap: $270.4M

See more data about RNAC stock on TipRanks’ Stock Analysis page.